Exploration and treatment of type 2 inflammation and asthma

I. Relationship between type 2 inflammation and asthmaAsthma is a complex aerobic disease, and its inflammatory response can be divided into two main types: type 2 and non-type 2 inflammation. Understanding these two types of inflammation is essential for the accurate treatment of asthma. In asthma, type 2 inflammation is usually manifested in an increase in high antibody drops and acidic particle cells, or an increase in the volume of the pneumatic nitrogen monoxide (FeNO). The typical characteristics of type 2 inflammation are dominated by cytogens such as IL-4, IL-5 and IL-13, which are usually produced by adaptive immune systems when they are irritated by allergy.Studies show that about 50 per cent of cases of severe asthma fall into the category of type 2 inflammation, while 80 per cent ~90 per cent of the medium-high-dose ICS treatment programme is driven by type 2 asthma. In addition, type 2 asthma patients are more vulnerable to the effects of environmental factors such as bacteria, viruses and allergies, as well as to co-infection with a range of type 2 inflammations, such as ad hoc dermatitis and allergic nasitis.II. Mechanisms for the incidence of type 2 inflammationThe mechanisms for the onset of type 2 inflammation cover many aspects, including the interaction of the built-in and adaptive immune systems. In asthma, Type 2 Immunoresponses include the inherently immune system (e.g. ILC2) and the adaptive immune system (e.g. Th2) cell type, which produce the key cell factors IL-4, IL-13 and IL-5 for type 2 inflammation. These cytofactors promote the functional impairment of the upper skin barrier in the airway through a variety of mechanisms, reduce the integrity of the upper skin connection and increase the permeability of the upper skin, thereby triggering arrhythmia and over-reaction.In addition, viruses, bacteria and irritants can also trigger type 2 inflammation by stimulating congenital immune systems. In this case, even if the patient does not have a clear history of allergies or an IGE-guided response, the characteristic manifestations of type 2 inflammation may occur.III. Type 2 asthma treatmentDiagnosisClinical symptoms assessment: Includes typical asthma symptoms such as cough, asthma and chest suffocation.Treatment Response Assessment: Observe patient response to asthma therapy.Biomarks assessment for type 2 inflammation: e.g., blood acidist particle count, FeNO level, slurry acidist particle count, etc. These biomarkers are important for identifying type 2 asthma.TreatmentDrug treatment: Based on the seriousness of the patient ‘ s condition, the appropriate medication is selected under the direction of a doctor. For type 2 asthma patients, commonly used drugs include inhaled cortical steroids (ICS), oral cortical steroids (OCS) and target treatments for critical cell factors of type 2 inflammation, such as IL-5, IL-4/IL-13 and IGE.Psychotherapy: To help patients understand the disease and to promote positive co-operation in treatment and improvement of the prognosis.Elimination of risk factors: environmental factors, co-existence of diseases, etc. Avoiding exposure to allergies, taking care to keep warm, and avoiding intense physical activity would also help to reduce asthma.IV. Outlook for the futureWith an in-depth study of the asthma regime, individualized treatment is becoming the mainstream direction for future asthma management. Depending on the patient ‘ s specific type of inflammation, allergy and other individual characteristics, tailored treatment programmes will help to improve treatment effectiveness, reduce adverse reactions and improve patient ‘ s long-term prognosis. In addition, the ongoing development and application of treatment drugs for new types of inflammation 2 will provide more effective treatment options for type 2 asthma patients.In summary, there is a strong correlation between type 2 inflammation and asthma. Through an in-depth understanding of the mechanisms for the onset of type 2 inflammation, an accurate diagnosis of type 2 asthma and individualized treatment, we can more effectively control asthma and improve the quality of life of patients.